… Neoangiogenesis and Blood-Brain Barrier in L-DOPA-induced Dyskinesia Levodopa is still the most effective treatment … a great potential to induce abnormal involuntary movements (dyskinesia). Working on a pre-clinical model of PD, we have … changes occurred only in pre-clinical models exhibiting dyskinesia in response to levodopa. Moreover, …

… levels of levodopa play a key role in the production of dyskinesia (abnormal involuntary movements) and motor … from blood to brain in a way that favours the occurrence of dyskinesia and motor fluctuations. Final Outcome Working in … levels of levodopa and dopamine during the expression of dyskinesia. In the same model, chronic treatment with …

… part of the brain called the striatum in levodopa-induced dyskinesia. This small population of striatal neurons has … activities of striatal cholinergic interneurons can alter dyskinesia. Study Design: We will test methods to modulate … We will inhibit the neuronal activity and study if dyskinesia can be prevented or reduced. Impact on …

… Neoangiogenesis and Blood-Brain Barrier in L-DOPA-induced Dyskinesia Promising Outcomes of Original Grant : Working on … correlates with the severity of the motor complications (dyskinesia) induced by levodopa. Treatments that inhibit … were found to significantly reduce the development of dyskinesia in the pre-clinical model. Objectives for …

… occur in Parkinson's disease and reduce the severity of dyskinesias. Dyskinesias are one of the major complications of standard … Parkinson's progression as well as levodopa-induced dyskinesias. Study Design: Our studies include two aims: Aim …

… new pharmacological approaches to treat levodopa-induced dyskinesia (LID) in a pre-clinical model of Parkinson’s … will also determine whether ROSI alters the expression of dyskinesia markers in the brain. assess whether PPARb/d, a … ameliorates levodopa-induced oral, axial and limb dyskinesias in 6-OHDA-treated pre-clinical models of …